ArticleZeitschrift fur Rheumatologie2019
[Health care and disease burden in persons with axial spondyloarthritis in Germany].
Article in Zeitschrift fur Rheumatologie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- [Rheumatological care of older people : Annual report 2026 from the National Database of the regional Collaborative Arthritis Centers].Zeitschrift fur Rheumatologie · 2026Article
- Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.Rheumatology international · 2024Article
- [Rheumatological care in Germany : Memorandum of the German Society for Rheumatology and Clinical Immunology 2024].Zeitschrift fur Rheumatologie · 2024Article
- [Dealing with NSAID in the treatment of axial spondylarthritis].Zeitschrift fur Rheumatologie · 2023Article
- [Apps in rheumatology : Is there a need for an app in therapy for axial spondyloarthritis?]Zeitschrift fur Rheumatologie · 2023Article
- [Prescription frequency of physical therapy for inflammatory rheumatic diseases].Zeitschrift fur Rheumatologie · 2022Article
- Prescription of analgesics in patients with rheumatic diseases in Germany : A claims data analysis.Zeitschrift fur Rheumatologie · 2021Article
- Treat-to-target in axial spondyloarthritis - what about physical function and activity?Nature reviews. Rheumatology · 2021Review
- [Prescription of analgesics in patients with rheumatic diseases in Germany : A claims data analysis. German version].Zeitschrift fur Rheumatologie · 2021Article
- The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study.Arthritis research & therapy · 2020Article
- [Cost of illness in axial spondylarthritis for patients with and without tumor necrosis factor inhibitor treatment: results of a routine data analysis].Zeitschrift fur Rheumatologie · 2020Article
- The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study.Therapeutic advances in musculoskeletal disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOnly very few data are available on the comprehensive care in patients with axial spondylarthritis (axSpA), one of the most frequent inflammatory rheumatic disease.
objectiveDescription of the comprehensive care and common prescription patterns of medications and other therapies in patients with axSpA depending on the type of medical care by rheumatologists or nonrheumatologists.
methodsA cross-sectional analysis was performed based on claims data of the BARMER health insurance company (in 2015) and a questionnaire, which was sent to a representative sample of patients with axSpA (International Classification of Diseases, 10th revision, German modification, ICD-10-GM, code M45) aged 18-79 years. A stratified sample of 5000 patients was used. The patients received a postal questionnaire including questions regarding the disease, health-related and psychological parameters and socioeconomic factors. Claims data consisted of demographic factors, medicinal and nonmedicinal treatment and the extra-articular manifestations inflammatory bowel disease, psoriasis and uveitis.
resultsA total of 1741 patients (mean age 55.9 years, female 46.4%, 86.2% Human Leucocyte Antigen[HLA]-B27 positive) confirmed the diagnosis and answered the questionnaire. The mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 4.5 and the mean Bath Ankylosing Spondylitis Functional Index (BASFI) 4.1. Of the patients 46% were treated by rheumatologists. There was a substantial difference between patients in rheumatological care and those who were not in rheumatological care regarding prescriptions for drug treatment of axSpA (91.8% versus 66.4%). This difference was especially prominent for prescriptions of biologic disease-modifying antirheumatic drugs: 34.1% of patients in rheumatological care versus 3.1% of patients treated by nonrheumatologists (p < 0.0001), despite similar disease activity in both groups.
conclusionThe data show that the majority of patients diagnosed with axSpA did not receive regular care from rheumatologists. This seemed to be associated with insufficient medicinal care at least in some of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.